Do you recommend to pool this control with patient sample after library prep, before NGS?
No issues.
Was this article helpful?
Yes
No
Still have questions? Contact Us
Synthetic Controls
cfDNA Pan-cancer
close menu
- What is your background cfDNA made from?
- Is your background cfDNA limited supply?
- Is background cfDNA from a mixed pool of donors?
- Are these control oligos, RNA, what is in it/ components?
- Does your product have matrics (e.g., synthetic plasma, plasma)?
- Do you shear donor derived background?
- Is there any concern for introduced bias for the expansion of cfDNA?
- How do you design the ctDNA/ variant list?
- What is the structure of the 3' and 5'?
- What is the WGS and WES setting to qualify the cfDNA material, and QC the Twist cfDNA?
- Were the mutations in the standards confirmed by NGS as well, as with digital PCR as it says in the document?
- How do we know we are very close to natural background cfDNA?
- What is the recommend input and dilution buffer?
- Can’t find indel or other hard to detect variants?
- What reagents (e.g., library prep) do you use for the liquid biopsy workflow?
- Do you recommend to pool this control with patient sample after library prep, before NGS?
- Are there different needs between amplicon and hybrid capture customers?
- Variant (COSM214499) is always high in 0% in NGS QC results, why?
- For NGS QC, do you use target capture sequence for the 458 variants or use a whole genome sequence?
